Diagnosis of IBD still remains a challenge for physicians. An ideal biomarker for IBD should be simple, easy to perform, noninvasive or microinvasive, cheap, rapid, and reproducible. Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC) with unknown etiology. Physicians get the diagnosis of IBD usually based on the combination of clinical features, laboratory tests, radiology, endoscopy, and pathology.
Laboratory biomarkers are noninvasive or microinvasive, objective, and rapid and cost less than other techniques, which relieve physiological and financial burden for patients. MARKERS RELATED TO DISEASE TYPE Antineutrophil Cytoplasmic Antibodies: Atypical perinuclear ANCA (pANCA) increases significantly in UC. A nation-based survey shows that the positive rate of pANCA is 55% in UC, 48% in rheumatoid arthritis, and 32% in healthy people.…
